KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Shares Outstanding (2016 - 2024)

Historic Shares Outstanding for Arbutus Biopharma (ABUS) over the last 16 years, with Q4 2024 value amounting to $190.0 million.

  • Arbutus Biopharma's Shares Outstanding rose 1183.04% to $190.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $190.0 million, marking a year-over-year increase of 1183.04%. This contributed to the annual value of $190.0 million for FY2024, which is 1183.04% up from last year.
  • As of Q4 2024, Arbutus Biopharma's Shares Outstanding stood at $190.0 million, which was up 1183.04% from $169.9 million recorded in Q4 2023.
  • Arbutus Biopharma's Shares Outstanding's 5-year high stood at $190.0 million during Q4 2024, with a 5-year trough of $69.0 million in Q1 2020.
  • For the 5-year period, Arbutus Biopharma's Shares Outstanding averaged around $126.4 million, with its median value being $145.0 million (2021).
  • Its Shares Outstanding has fluctuated over the past 5 years, first soared by 6167.46% in 2021, then soared by 788.29% in 2023.
  • Quarter analysis of 5 years shows Arbutus Biopharma's Shares Outstanding stood at $89.7 million in 2020, then surged by 61.67% to $145.0 million in 2021, then grew by 8.6% to $157.5 million in 2022, then grew by 7.88% to $169.9 million in 2023, then increased by 11.83% to $190.0 million in 2024.
  • Its last three reported values are $190.0 million in Q4 2024, $169.9 million for Q4 2023, and $165.1 million during Q1 2023.